Pliant Therapeutics (PLRX) Income towards Parent Company (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Income towards Parent Company of -$57.3 million for Q1 2026, up 4.32% year-over-year from -$54.9 million in Q1 2025, and down 281.73% quarter-over-quarter from -$15.0 million in Q4 2025.
Pliant Therapeutics (PLRX) Income towards Parent Company (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Income towards Parent Company for 8 consecutive years, with -$57.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 4.32% year-over-year to -$57.3 million; the TTM figure through Mar 2026 stood at -$187.7 million (up 21.15% YoY), while the FY2025 annual figure was -$374.5 million, up 12.27% from the prior year.
- Income towards Parent Company retreated to -$57.3 million in Q1 2026 per PLRX's latest filing, from -$15.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$15.0 million in Q4 2025 and bottomed at -$86.3 million in Q2 2025.
- Historically, Income towards Parent Company has averaged -$47.6 million across 5 years, with a median of -$48.6 million in 2023.
- Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 75.63% — and 2025, when it soared 72.71%.
- Pliant Therapeutics' Income towards Parent Company stood at -$35.8 million in 2022, then sank by 75.63% to -$62.9 million in 2023, then rose by 12.5% to -$55.0 million in 2024, then jumped by 72.71% to -$15.0 million in 2025, then tumbled by 281.73% to -$57.3 million in 2026.
- Business Quant data shows PLRX's Income towards Parent Company at -$57.3 million in Q1 2026, -$15.0 million in Q4 2025, and -$29.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.37 Mn |
| Mar 31, 2026 | -57.31 Mn |
| Dec 31, 2025 | -15.01 Mn |
| Sep 30, 2025 | -29.05 Mn |
| Jun 30, 2025 | -86.29 Mn |
| Mar 31, 2025 | -59.90 Mn |
| Dec 31, 2024 | -55.02 Mn |
| Sep 30, 2024 | -61.43 Mn |
| Jun 30, 2024 | -61.64 Mn |
| Mar 31, 2024 | -53.73 Mn |
| Dec 31, 2023 | -62.88 Mn |
| Sep 30, 2023 | -47.67 Mn |
| Jun 30, 2023 | -48.56 Mn |
| Mar 31, 2023 | -41.78 Mn |
| Dec 31, 2022 | -35.80 Mn |
| Sep 30, 2022 | -33.44 Mn |
| Jun 30, 2022 | -30.15 Mn |
| Mar 31, 2022 | -29.56 Mn |
| Dec 31, 2021 | -23.46 Mn |
| Sep 30, 2021 | -27.15 Mn |